Patents by Inventor Craig A. Rosen

Craig A. Rosen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Albumin Fusion Proteins
    Publication number: 20080293629
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.
    Type: Application
    Filed: July 2, 2007
    Publication date: November 27, 2008
    Inventors: Craig A. Rosen, William A. Haseltine
  • Human G-Protein Coupled Receptor
    Publication number: 20080287388
    Abstract: A human G-protein coupled receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for identifying antagonists and agonists to such polypeptide. Antagonists and agonists may be used therapeutically to inhibit or stimulate the G-protein coupled receptor. Also disclosed are assays for detecting mutations in the nucleic acid sequence encoding the G-protein coupled receptor.
    Type: Application
    Filed: June 25, 2008
    Publication date: November 20, 2008
    Applicant: Human Genome Sciences, Inc.
    Inventors: Yi Li, Craig A. Rosen
  • Vascular endothelial growth factor 2
    Publication number: 20080286288
    Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
    Type: Application
    Filed: October 31, 2007
    Publication date: November 20, 2008
    Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
  • Death domain containing receptor 4 antibodies and methods
    Patent number: 7452538
    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: November 18, 2008
    Assignees: Human Genome Sciences, Inc., The Regents of the University of Michigan
    Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
  • Myeloid Progenitor Inhibitory Factor-1 (MPIF-1), Monocyte Colony Inhibitory Factor (M-CIF), and Macrophage Inhibitory Factor-4 (MIP-4)
    Publication number: 20080274109
    Abstract: There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine ?8 (CK?8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-? and chemokine ?1 (CK?1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.
    Type: Application
    Filed: April 28, 2008
    Publication date: November 6, 2008
    Applicant: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Brent L. Kreider, Jun Zhang, Michael Antonaccio, Donna Mendrick, Pablo Jimenez, Vikram Patel, Craig A. Rosen, Mark D. Adams, Haodong Li, Steven M. Ruben
  • Human tumor necrosis factor receptor-like 2
    Patent number: 7446169
    Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: November 4, 2008
    Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corporation
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz, Sally Doreen Patricia Lyn, Mark Robert Hurle
  • Soluble Interleukin-1 Receptor Accessory Molecule
    Publication number: 20080261252
    Abstract: The present invention relates to a novel soluble IL-1 receptor accessory molecule (IL-1R AcM) protein which is a member of the Ig superfamily. In particular, isolated nucleic acid molecules are provided encoding the human IL-1R AcM protein. IL-1R AcM polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Screening methods are further provided for identifying agonist and antagonists of IL-1 signal transduction. The invention further relates to methods for treating physiologic and pathologic disease conditions with IL-1R AcM antagonists.
    Type: Application
    Filed: June 11, 2008
    Publication date: October 23, 2008
    Applicant: Human Genome Sciences, Inc.
    Inventors: Daniel P. Bednarik, Henrik S. Olsen, Craig A. Rosen
  • Vascular endothelial growth factor 2
    Patent number: 7439333
    Abstract: Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA (RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: October 21, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jing-Shan Hu, Craig A. Rosen, Liang Cao
  • Death domain containing receptor 5
    Publication number: 20080248046
    Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which may be agonists and/or antagonists of DR5 activity.
    Type: Application
    Filed: January 18, 2008
    Publication date: October 9, 2008
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
  • Death domain containing receptor 4
    Publication number: 20080241155
    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.
    Type: Application
    Filed: January 18, 2008
    Publication date: October 2, 2008
    Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
  • Antibodies to human tumor necrosis factor receptor-like 2
    Patent number: 7429646
    Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: September 30, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz
  • Antibodies That Specifically Bind to Chemokine Beta-4
    Publication number: 20080233134
    Abstract: The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-B4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
    Type: Application
    Filed: May 19, 2008
    Publication date: September 25, 2008
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: Craig A. Rosen, Steven M. Ruben
  • Polynucleotides encoding human tumor necrosis factor receptor-like2
    Patent number: 7427492
    Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: September 23, 2008
    Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corporation
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz
  • Human Genes, Sequences and Expression Products
    Publication number: 20080227110
    Abstract: Human polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for therapeutic purposes. Antagonists against such polypeptides and their use as a therapeutic are also disclosed. Also disclosed are diagnostic methods for detecting disease which utilize the sequences and polypeptides.
    Type: Application
    Filed: February 25, 2008
    Publication date: September 18, 2008
    Applicant: Human Genome Sciences, Inc.
    Inventors: Paul A. Moore, Reiner L. Gentz, Henry Hongjun Ji, Jian Ni, Jing-Shan Hu, Craig A. Rosen
  • Chemokine Beta-15
    Publication number: 20080226586
    Abstract: The present invention concerns a member of the human chemokine CC protein family. In particular, isolated nucleic acid molecules are provided encoding the chemokine ?-15 protein. Chemokine ?-15 polypeptides are also provided. The invention further concerns diagnostic methods for detecting thymus disorders and therapeutic methods for modulating bone marrow cell proliferation and differentiation.
    Type: Application
    Filed: October 2, 2006
    Publication date: September 18, 2008
    Applicant: Human Genome Sciences, Inc.
    Inventors: Ying-Fei Wei, Brent Kreider, Craig Rosen
  • Antibodies against C3a receptor
    Patent number: 7425622
    Abstract: The present invention relates to antibodies and related molecules that specifically bind to C3a Receptor. Such antibodies have uses, for example, in the prevention and treatment of asthma, allergy, and other related inflammatory and immune disorders. The invention also relates to nucleic acid molecules encoding anti-C3a Receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially inflammatory and other related disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to C3a Receptor.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: September 16, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventor: Craig A. Rosen
  • Albumin fusion proteins
    Publication number: 20080213886
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Application
    Filed: May 8, 2006
    Publication date: September 4, 2008
    Applicant: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
  • Immunoassay methods for detecting interleukin-1 ? converting enzyme like apoptosis protease-3
    Patent number: 7416855
    Abstract: Disclosed are human interleukin-1 ? converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor agent, and antiviral agent, and antibodies and antagonists against such polypeptides for example, for treating Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and head injury. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: August 26, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Wei-Wu He, Craig A. Rosen, Peter L. Hudson, Gregg A. Hastings
  • Albumin Fusion Proteins
    Publication number: 20080194481
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Application
    Filed: October 31, 2007
    Publication date: August 14, 2008
    Inventors: Craig A. Rosen, Adam Bell, Paul A. Moore, Yanggu Shi, David LaFleur, Jason B. Bock, Michael W. Laird, William A. Haseltine, Douglas B. Woods, Mani Subramanian
  • Antibodies to HDPPA04 polypeptide
    Patent number: 7411051
    Abstract: The present invention relates to antibodies that specifically bind HDPPA04 polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said HDPPA04. Also encompassed by the invention are host cells and hybridomas for producing said antibodies. The invention further encompasses methods for detecting said HDPPA04 polypeptides using said antibodies.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: August 12, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben